Brief: Tandem Diabetes Care Q2 Operating Income USD -51.8 Million

Tandem Diabetes Care

06/08/2025 21:05

Overview

Tandem Diabetes Q2 sales rise to $240.7 mln, achieving record sales

Adjusted operating loss missed analyst expectations, per LSEG data

Co expects to reach $1 bln in sales for full year 2025

Outlook

Tandem expects 2025 sales to reach $1 bln worldwide

Company forecasts $700 mln U.S. sales in 2025

Company anticipates $300 mln sales outside U.S. in 2025

Tandem sees 2025 adj EBITDA margin at negative 5%

Result Drivers

RECORD SALES - Achieved record second quarter sales in the U.S. and internationally

U.S. PUMP SHIPMENTS - Increased U.S. pump shipments contributed to sales growth, per CEO John Sheridan

TECHNOLOGY INTEGRATION - Early access program for t:slim X2 with Control-IQ+ technology integrated with Abbott’s FreeStyle Libre 3 Plus sensor initiated

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Net Income
Miss
-$32.40 mln
-$27 mln (17 Analysts)
Q2 Net Income
-$52.40 mln
Q2 Gross Margin
52.0%
Q2 Adjusted Operating income
Miss
-$31.90 mln
-$26.90 mln (18 Analysts)
Q2 Operating income
-$51.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 11 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Tandem Diabetes Care Inc is $27.00, about 43.9% above its August 5 closing price of $15.15

Press Release: ID:nBw8FvgmFa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)